Loading...
•
Dec 31, 2021
Pulmonx Q4 2021 Earnings Report
Reported a 39% increase in worldwide revenue and a gross margin of 74.8%.
Key Takeaways
Pulmonx Corporation reported a 39% increase in worldwide revenue for the fourth quarter of 2021, reaching $13.7 million. The company's gross margin also improved to 74.8%. Despite COVID headwinds, the company expanded its base of U.S. treatment centers and submitted a regulatory filing seeking Zephyr Valve approval in Japan.
Worldwide revenue increased by 39% to $13.7 million compared to Q4 2020.
Gross margin improved to 74.8% from 72.0% in the same period of 2020.
U.S. revenue increased by 49% compared to the fourth quarter of 2020.
Submitted regulatory filing seeking Zephyr Valve approval in Japan in December 2021
Revenue by Geographic Location
Forward Guidance
Pulmonx expects revenue for the full year 2022 to be in the range of $55 million to $60 million. Taking into account the ongoing impact of COVID-19, Pulmonx expects revenue for the first quarter 2022 to be in the range of $9 million to $10 million. The Company expects total operating expenses for the full year 2022 to fall within the range of $100 million to $105 million inclusive of stock-based compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...